Luc Meuleners
Overview
Explore the profile of Luc Meuleners including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Timmis H, Van Kaem T, Desrivot J, Dupont S, Meuleners L, Beetens J, et al.
Clin Pharmacol Drug Dev
. 2021 May;
10(9):994-1006.
PMID: 33960725
GLPG1205 is a modulator of GPR84, a G-protein-coupled receptor reported to be associated with several diseases. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1205 in healthy subjects were evaluated in 2...
2.
Kavanaugh A, Westhovens R, Winthrop K, Lee S, Tan Y, An D, et al.
J Rheumatol
. 2021 Feb;
48(8):1230-1238.
PMID: 33526618
Objective: The long-term safety and efficacy of filgotinib (from phase II studies), with or without methotrexate (MTX), for the treatment of patients with rheumatoid arthritis was assessed in DARWIN 3,...
3.
Orbai A, Ogdie A, Gossec L, Tillett W, Leung Y, Gao J, et al.
Rheumatology (Oxford)
. 2019 Oct;
59(7):1495-1504.
PMID: 31624837
Objective: To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in...
4.
van der Heijde D, Baraliakos X, Gensler L, Maksymowych W, Tseluyko V, Nadashkevich O, et al.
Lancet
. 2018 Oct;
392(10162):2378-2387.
PMID: 30360970
Background: At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs (NSAIDs)....
5.
Mease P, Coates L, Helliwell P, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, et al.
Lancet
. 2018 Oct;
392(10162):2367-2377.
PMID: 30360969
Background: The Janus kinase 1 (JAK1) pathway has been implicated in the pathogenesis of psoriatic arthritis. We aimed to investigate the efficacy and safety of filgotinib, a selective JAK1 inhibitor,...
6.
Genovese M, Westhovens R, Meuleners L, Van der Aa A, Harrison P, Tasset C, et al.
Arthritis Res Ther
. 2018 Mar;
20(1):57.
PMID: 29566740
Background: The aim was to assess patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib during two phase 2b, 24-week, randomized, placebo-controlled studies. Methods: Patients with moderate-to-severe...
7.
Vanhoutte F, Mazur M, Voloshyn O, Stanislavchuk M, Van der Aa A, Namour F, et al.
Arthritis Rheumatol
. 2017 Jun;
69(10):1949-1959.
PMID: 28622463
Objective: JAK inhibitors have shown efficacy in rheumatoid arthritis (RA). We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better...
8.
Singh D, Piccinno A, Borrill Z, Poli G, Acerbi D, Meuleners L, et al.
Pulm Pharmacol Ther
. 2008 Mar;
21(3):551-7.
PMID: 18321744
The corticosteroid beclomethasone dipropionate (BDP) has been formulated with the long acting beta agonist formoterol (BDP/formoterol 100 microg/6 microg, Foster) in a single inhaler using Modulite technology. We have investigated...